Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 7/20 | 0.63 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.55 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2785238 | 1.00 | PIM1 (0.63) | PIM1PIM2AKR1B1HPGDADAMTS5 | |
| SCHEMBL5800236 | 0.88 | HPGD (0.64) | PIM1PIM2AKR1B1HPGD | |
| SCHEMBL3291603 | 0.88 | HPGD (0.64) | PIM1PIM2AKR1B1HPGD | |
| SCHEMBL2546852 | 0.82 | PIM1 (0.70) | PIM1PIM2AKR1B1ADAMTS5CISD1 | |
| SCHEMBL2546853 | 0.82 | PIM1 (0.70) | PIM1PIM2AKR1B1ADAMTS5CISD1 | |
| SCHEMBL2174556 | 0.81 | PDE4B (0.68) | PIM1PIM2HPGDGSK3B | |
| SCHEMBL2172862 | 0.81 | HPGD (0.68) | HPGD | |
| SCHEMBL2786377 | 0.81 | HPGD (0.68) | HPGD | |
| SCHEMBL2173332 | 0.80 | HPGD (0.56) | PIM1PIM2HPGD | |
| SCHEMBL2785066 | 0.80 | HPGD (0.56) | PIM1PIM2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | claimed |
| EP-2254576-B1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | UNIV OHIO STATE RES FOUND (US) | 2013-08-28 | — | — | EP | disclosed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2254576-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | The Ohio State University Research Foundation (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009105621-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | AR, ESRRB, KLK3 | PIM1 4023/4885PIM2 3662/4885AKR1B1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.